.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,933,120

« Back to Dashboard

Claims for Patent: 8,933,120

Title:Enhanced bimatoprost ophthalmic solution
Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
Inventor(s): Chang; Chin-Ming (Tustin, CA), Chang; James N. (Newport Beach, CA), Schiffman; Rhett M. (Laguna Beach, CA), Jordan; R. Scott (Trabuco Canyon, CA), Chang-Lin; Joan-En (Tustin, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:14/100,914
Patent Claims: 1. An ophthalmic composition comprising about 0.01%-0.015% w/v bimatoprost and about 0.02% w/v benzalkonium chloride.

2. The ophthalmic composition of claim 1, wherein the composition comprises about 0.01% w/v bimatoprost.

3. The ophthalmic composition of claim 1, wherein the composition comprises 0.01% w/v bimatoprost.

4. The ophthalmic composition of claim 1, wherein the composition comprises about 0.015% w/v bimatoprost.

5. The ophthalmic composition of claim 1, wherein the composition comprises 0.015% w/v bimatoprost.

6. The ophthalmic composition of claim 1, wherein the composition comprises 0.02% w/v benzalkonium chloride.

7. The ophthalmic composition of claim 1, wherein the composition further comprises dibasic sodium phosphate.

8. The composition of claim 1, wherein the first composition further comprises citric acid monohydrate.

9. The composition of claim 1, wherein the composition further comprises sodium chloride.

10. The composition of claim 1, wherein the first composition further comprises hydrochloric acid and sodium hydroxide to adjust the pH.

11. The composition of claim 1, wherein the composition further comprises water.

12. The composition of claim 1, wherein the first composition has a pH of about 7.3.

13. The composition of claim 1, wherein the composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride, and when applied to the eyes of a human patient suffering from elevated intraocular pressure, lowers intraocular pressure and results in less hyperemia than a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride.

14. The composition of claim 13, wherein the composition applied once daily lowers intraocular pressure as effectively as the second composition applied once daily.

15. The composition of claim 13, wherein the composition is applied to the eyes of a human patient suffering from elevated intraocular pressure at least once a day.

16. The composition of claim 13, wherein the composition applied once daily lowers intraocular pressure more effectively than the second composition applied once daily.

17. The composition method of claim 13, wherein the composition applied once daily is effective for treating glaucoma.

18. The composition of claim 1, wherein the composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride, and when applied once daily to the eyes of a human patient suffering from elevated intraocular pressure, lowers intraocular pressure and results in less hyperemia than a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride.

19. The composition of claim 18, wherein the composition applied once daily lowers intraocular pressure as effectively as the second composition applied once daily.

20. The composition method of claim 18, wherein the composition applied once daily is effective for treating glaucoma.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc